In general. I think it's almost the perfect acquisition for Ktov. Price paid, combination drug, market potential, ect... my only concern is cash. Which a licensing deal would take care of no problem, say 20 million upfront. I'm thinking our 18million took some nice whack downs recently. 2 million renal study, 2 million acquisition, 2 million for last 6 month operating expenses plus attorney fees for acquisition. Maybe I'm wrong but I put cash around 10-12 million. Which is still good for having no debt. But, if no deal on kit in 3 months will they be tempted to do another offering to help fund new trials and operating expenses. That's my only concern here. Other than that. Acquisition was good, imo.
News 
Market Data 
Discover 
